
Oncology NEWS International
- Oncology NEWS International Vol 17 No 7
- Volume 17
- Issue 7
RAS Mutations Enhance Chemotherapy in AML
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.
Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.
Articles in this issue
almost 18 years ago
National Cancer Survivors Dayalmost 18 years ago
New Indication for Velcade in Previously Untreated Myelomaalmost 18 years ago
Risk Factors for Mantle Cell Lymphoma Identifiedalmost 18 years ago
Antidiabetic Agent Metformin May Boost pCRs in Breast Caalmost 18 years ago
Eisai Seeks Full FDA Approval for Ontak for CTCLalmost 18 years ago
Symptom Screen Plus CA125 Detects Early Ovarian Caalmost 18 years ago
Cisplatin Linked to Cardiac Complications in Testicular Ca Patientsalmost 18 years ago
Updated X-ACT Study Results Presentedalmost 18 years ago
ThromboGenics and BioInvent Announce Alliance with Rochealmost 18 years ago
Gene Signature Identifies Low-Risk Patients in MAGE-A3 TrialNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content



130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study















































